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The aim of this work was to determine the susceptibility, molecular profile, and clonal relationship in Strep-
tococcus agalactiae (group B Streptococcus [GBS]) isolated from vaginal-rectal swab samples. We worked
with 200 isolates collected from pregnant women between 35 and 37 weeks of gestation. The macrolide–
lincosamide–streptogramin B (MLSB) resistance phenotypes were determined using the double-disc assay.
Susceptibility to erythromycin (ERI) and clindamycin (CLI) was performed with the E-test. Resistance genes
ermB and ermTR were detected by polymerase chain reaction. Clonal studies were performed using the random
amplification of polymorphic DNA. Twelve (6%) of the isolates were resistant to ERI and 10 (5%) of them to
CLI. Fifty percent of the resistant strains corresponded to serotype III, 25% to serotype V, and the remaining
25% to serotype Ia, II, and nontypeable strains. The cMLSB phenotype was detected in eight strains (66.67%)
and the iMLSB phenotype in four (33.33%). The minimum inhibitory concentration values were between 1.5
and 16 mg/mL for ERI, and between 1 and 32mg/mL for CLI. Out of the 25 strains susceptible to ERI and CLI,
the presence of the ermB gene was detected in eight of them and the ermTR gene in one strain. The ermB gene
was detected in the 12 strains that initially had some macrolide resistance phenotype. The ermTR gene was
detected in three out of the four strains with the iMLSB phenotype. The resistance to macrolides in the province
of Misiones is due to multiclonal spread. The phenotypic and genotypic characterization of macrolide resistance
in GBS strains are crucial to contribute to the correct intrapartum prophylactic antibiotic therapy of allergic
pregnant women and the epidemiological surveillance of these strains.
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Introduction
Streptococcus agalactiae, also called group BStreptococcus (GBS), was initially recognized in 1887
by Nocard and Mollereau as an infectious agent of bovine
mastitis.1 In 1879, Pasteur detected similar microorganisms
in the blood of a patient with puerperal sepsis. It follows that
these were the first GBS identified. These microorganisms
were isolated by Lancefield and Hare from vaginal cultures
of asymptomatic postpartum women in 1935 and identified
for the first time as human pathogens that caused three cases
of fatal puerperal fever in 1938.2
During the following years, GBS was not isolated from
human infections. In 1970, it became relevant as an etio-
logical agent, not only in adults as an emerging disease in
nursing homes and intensive care units, which caused a
change of paradigm in the epidemiological control of
GBS,3 but also in neonates, in which it still is the leading
cause of severe invasive infections, as well as in infants
younger than 3 months. Meningitis, pneumonia and sepsis,
the major infections in these children, are described as the
most serious illnesses that individuals can suffer in their
first hours of life.4 It is important to note that GBS and
Escherichia coli are responsible for 23% and 42%, re-
spectively, of bacteremias in children younger than 90
days.5 Statistics indicate that 50% of children born to
mothers carrying GBS will be colonized by this microor-
ganism. Out of these children, 1% will develop invasive
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disease. As a result of preventive efforts, the overall inci-
dence of invasive neonatal GBS infection has declined
significantly over the past few years.6
Streptococcus agalactiae has a rhamnose-glucosamine
polymer bound to the peptidoglycan layer, an antigen combi-
nation that characterizes it as the only member of group
B. Classification within the 10 existing serotypes (Ia, Ib, II, III,
IV, V, VI, VII, VIII, and IX) is due to the different capsular
dispositions of glucose, galactose, N-acetylglucosamine, and
acid N-acetylneuraminic acid.7 The prevalence of the different
capsular serotypes of group B streptococci varies over time and
may differ from place to place. Epidemiological surveillance of
this distribution is important for the choice of conjugate vac-
cines currently under evaluation to achieve adequate coverage.8
To prevent neonatal infection, the Center for Disease
Prevention and Control, Atlanta, recommends testing for
GBS in all pregnant women between 35 and 37 weeks of
gestation by vaginal (anterior third) and anorectal swab-
bing.3 Although colonization in the first weeks of pregnancy
is not predictive of the subsequent risk of neonatal sepsis,
determination of the presence of GBS at any concentration,
and even at any stage of pregnancy, is considered one of the
factors determining intrapartum prophylaxis, without the
need to perform screening at weeks 35–37.9 Colonization
during pregnancy does not necessarily imply colonization in
subsequent pregnancies; therefore, a culture must be per-
formed at each new gestation. As a result of these preventive
efforts, the overall incidence of invasive neonatal GBS in-
fection has declined significantly all over the world over the
past 15 years.3
At present, intrapartum prophylactic antibiotic therapy is
implemented in women colonized by GBS up to 5 weeks
before delivery, whether or not they present some of the risk
factors mentioned above. Penicillin is the first-line drug for
the treatment of GBS infections and for intrapartum pro-
phylaxis.10 However, some researchers have demonstrated
microorganism tolerance to these antibiotics by both phe-
notypic and molecular approaches. This property was as-
signed to the substitution of amino acids adjacent to the
conserved SSN and KSG domains of the 2X penicillin
binding protein (PBP 2X), suggesting that it contributes to
treatment failure.11
Because of the above mechanisms and the existence of
patients who are allergic to penicillin, it is necessary to use
alternative antimicrobials such as macrolides and lincosa-
mides, a group of antibiotics structurally characterized by a
macrocyclic ring bound to two sugars. Among them,
erythromycin (ERI) and clindamycin (CLI) are used as
second-choice antibiotics in these cases. The mechanism of
action of these antibiotics is the binding to the 50S subunit
of bacterial ribosomes, thus inhibiting protein synthesis.12
In recent years, there has been an increase in antibiotic
resistance of the macrolide–lincosamide–streptogramin B
(MLSB) group in GBS strains. The two main mechanisms of
resistance are modifying the target site and active efflux.13
The target modification above occurs because erm genes
(erythromycin ribosomal methylase), ermB and ermA
(ermTR subclass), mediate the methylation of the 23S sub-
unit of rRNA, thus causing a conformational change in the
prokaryotic ribosome and blocking the binding of macro-
lides, lincosamides, and streptogramin B to their binding site
in the 50S subunit.14
The ability of GBS to generate resistance to ERI and CLI
has two variables: the constitutive resistance cMLSB and the
inducible iMLSB, related to the expression of ermB gene
and ermTR, respectively. The constitutive variable presents
a high level of resistance to any antimicrobial of the MLSB
group. In contrast, the inducible way presents resistance to
macrolides of 14 atoms (ERI) and 15 atoms (azithromycin),
and in vitro susceptibility to macrolides of 16 atoms, CLI,
and streptogramins B. In iMLSB strains, the expression of
the erm genes is strongly induced by ERI, whereas CLI is a
weak inducer that acts slowly, so strains with iMLSB re-
sistance appear in vitro susceptibility to CLI, but, when used
clinically, in vivo self-induced resistance occurs with con-
sequent therapeutic failure.
The double-disc test (D-test), recommended by the
Clinical and Laboratory Standards Institute (CLSI)15 to be
used for the detection of the iMLSB mechanism as a test of
the phenotype expression, is of great utility in presaging the
mutation toward in vivo constitutive resistance.16 These
mechanisms cannot be detected using either conventional
disk diffusion methods or by standard broth or plate dilution
methods.
The World Health Organization recommends surveil-
lance of antibiotic susceptibility and contribution to the
knowledge of the dissemination of resistance mechanisms
or clones, bearing these characteristics to define new
treatment strategies in each region. Several epidemiologi-
cal studies carried out on GBS isolates are based on ser-
otyping techniques; however, these traditional procedures
have both low discriminatory power and low reproduc-
ibility under different environmental or culture conditions,
as well as the disadvantage of the existence of nontyping
strains.17 Over the last two decades, different groups have
developed molecular techniques to study genetic diversity
among closely related organisms, such as restriction frag-
ment length polymorphisms, pulsed field gel electropho-
resis, electrophoresis of multilocus enzymes, and random
amplification of polymorphic DNA (RAPD), which have
been used effectively to determine subtypes of isolates of
human origin.18
In recent years, the RAPD technique has been used ex-
tensively for the determination of the epidemiological re-
lationship between GBS isolates. Genetic mapping using the
RAPD technique has numerous advantages over other
methods, for example, the use of ‘‘universal’’ primers for
the analysis of a wide variety of species. Preliminary work,
such as sequencing or cloning by DNA probes, is not re-
quired, thus optimizing the time to obtain results and re-
search costs.19
From the epidemiological point of view, it is important
to improve the characterization of the resistance to mac-
rolides and lincosamides of GBS so as to define whether
the observed resistance is due to dispersion of a specific
clone, or to the acquisition of various resistance mecha-
nisms of different clones. Therefore, the aim of this work
was to determine the susceptibility to ERI and CLI, mo-
lecular profile, and clonal relationship in Streptococcus
agalactiae isolated from vaginal-rectal swab samples col-
lected from women at 35 to 37 weeks of gestational age
attending the ‘‘Ramón Madariaga’’ Central Hospital and
peripheral Primary Health Care centers during the January
2004 to December 2014 period.

























































A total of 200 isolates recovered from vaginal-rectal swab
samples were collected from women at 35–37 weeks of ges-
tational age attending either the ‘‘Ramón Madariaga’’ Central
Hospital or peripheral Primary Health Care centers from
Misiones province, Argentina. The swabs were placed in
Stuart transport media (Ventura Transystem-Medica-Tec Ar-
gentina) and transported to the laboratory at room temperature
for microbiology analysis and determination of the serotype.20
The isolates were kept in skim milk at 20% and at -80C.21
Susceptibility tests by diffusion
The MLSB resistance phenotypes were determined using
the D-test assay with ERI (15mg) and CLI (2 mg) discs
supplied by Britania (Argentina), according to the recom-
mendations and interpretation of the CLSI.15
Determination of minimum inhibitory concentration
Susceptibility to ERI and CLI was performed with the
E-test by using strips provided by Oxoid (United Kingdom)
and BioMérieux (Marcy-l’Etoile, France), respectively. The
results were interpreted according to CLSI recommenda-
tions.15 The Staphylococcus aureus ATCC 25923 strain was
used as control.
Molecular detection of macrolide resistance genes
Isolates that showed resistance phenotypes with the dif-
fusion technique and other 25 isolates that were susceptible
to ERI and CLI were selected. Resistance genes ermB and
ermTR were detected by polymerase chain reaction (PCR).22
The primers used to detect resistance genes were designed
with the Primer3 version 0.4.0 software23 using complete
sequences for each gene available at the National Center for
Biotechnology Information (NCBI). Their respective se-
quence, and the melting temperature (TM) used during the
PCR reaction are shown in Table 1. Whole DNA was ob-
tained according to the protocol described by Sambrook and
Rusell24 modified by Cariaga Martinez and Zapata.25 The
sequencing of the PCR products was performed by Macrogen.
Positive controls were provided by the Antimicrobial Service
of the Argentine Reference Institute ‘‘Dr. Carlos G. Malbrán
(National Institute of Infectious Diseases—A.N.L.I.S.)’’:
Streptococcus pneumoniae AZ1: Gene ermB26 and Strepto-
coccus agalactiae 6394: Gen ermTR.27 Besides, a negative
control, consisting of the same reaction mixture but with
water instead of template DNA, was included in each run.
PCR amplification technique
The PCR was performed with 20 ng DNA at a final volume
of 20mL containing 1 · Taq DNA polymerase buffer (10 · :
500 mM KCl and 100 mM Tris-HCl, pH 9.0 at 25C; 1%
TritonX-100), 200mM of each dNTP, 10 pmol of each pri-
mer, and 0.5 U of the Taq DNA polymerase enzyme (Inbio
Highway, Argentina). The optimization of the technique
(setup for each gene) was performed with concentrations of
MgCl2 (Taq DNA polymerase co-enzyme) of 1.5, 2, and
3 mM. The cycling schedule applied to each PCR reaction
was performed by predenaturation at 94C for 2 min followed
by 30 cycles (30 sec at 94C, 60 sec at 50C, and 60 sec at
72C), and final elongation at 72C for 2 min, in a Multigene
TM II thermocycler (Labnet International, Inc.). Amplicons
were visualized on 2% (w/v) agarose gels and photographed
with a Cannon Power Shot G10 digital camera. The TM used
varied according to the primer used for each virulence gene
(Table 1).
DNA sequence analysis
The sequences obtained were analyzed in silica with a
BLASTn algorithm available at NCBI. The analysis was
based on similarity to sequences aligned in the BLAST
search.
Nucleotide sequence accession numbers
The nucleotide sequences reported in this article have been
submitted to the GenBank/EMBL sequence database and
assigned accession No. MG252535 (for the ermB gene from
Streptococcus agalactiae strain 369/10) and MG252536 (for
the ermTR gene from Streptococcus agalactiae strain 1090).
Statistical analysis of the results obtained
The results were statistically analyzed with the SPSS
version 19 software using the Chi-square test when the value
in each box exceeded 5 and Fisher’s exact test when it was
lower than 5 to evaluate if there were significant differences.
The confidence interval for proportions was calculated using
the formula p – za/2 [p(1 - p)/n]1/2, where p is the observed
proportion for each variable and n the total number of in-
dividuals analyzed. We considered that for dichotomous
populations with a success rate p, the point estimator of the
parameter is the sample success ratio p, which coincides with
the sample mean when the characteristic that is considered
success is coded as 1, while the one considered not suc-
cessful is coded as 0. For a moderately large sample size, the
p-statistic has an approximately normal distribution.
RAPD technique
Clonal studies were performed using the RAPD-RAPD
technique.18 The primers OPS11 (5¢AGTCGGGTGG3¢),
OPB17 (5¢AGGGAACGAG3¢), and OPB18 (5¢CCACAGC
AGT3¢)28 were selected. To evaluate the utility of each
primer to select nongenetically related isolates, the Hunter
Table 1. Sequences of Data Used in Polymerase Chain Reaction to Amplify Resistance Genes
in Streptococcus agalactiae Strains
Genes Sense 5¢-3¢ Antisense 5¢-3¢ Amplicon (bp) Tm (C)
ermB GAAAAAGTACTCAACCAAATA AGTAATGGTACTTAAATTGTTTAC 639 50
ermTR TTGGGTCAGGAAAAGGA GGGTGAAAATATGCTCG 385 50























































and Gaston formula29 was used to return the Index of Dis-
crimination (D), which must be >0.90 for the interpretation
of reliable typing results.
RAPD amplification
The PCR reaction was performed with 50 ng DNA in a
final volume of 50 mL containing 1 · of Taq DNA poly-
merase buffer (10 · : 500 mM KCl, 100 mM Tris-HCl, pH
9.0 at 25C, and 1% TritonX-100), 100 mM of each dNTP,
0.4 mM of each primer, and 2.5 U of the enzyme Taq DNA
polymerase (Inbio Highway).
A concentration of MgCl2 of 2.5 mM was used, the cy-
cling conditions being as follows: 5 min at 94C; 40 cycles
of 1 min at 94C, 1 min at 36C, and 1 min at 72C; and
5 min at 72C. The electrophoretic run was performed on
1.2% agarose gel at 100 V for 3 hr. The gels were stained
with GelRed, in an electrophoretic cell with subsequent
observation of the bands in a UV transilluminator.
Analysis of RAPD data
The band patterns obtained were normalized and com-
pared to each other by visual inspection. On the basis of
migration distance, the size of the different bands was
measured and interpolated at the corresponding molecular
weight marker using the GraphPad Prism software. Differ-
ent patterns were considered those differing in more than
four bands.
Each RAPD profile was analyzed for the presence (1) or
absence (0) of each defined band. The binary matrix ob-
tained was analyzed using Software Treecon 1.3b, which
generated a dendrogram or tree of similarity to establish the
relationships between the studied strains. We used the Nei
and Li algorithm to calculate genetic distances. The
grouping analysis was performed by unweighted pair group
method with arithmetic mean clustering, and its robustness
was corroborated by a bootstrap of 1,000 replicates. In ad-
dition, the reference strain S. agalactiae SS 615 well char-
acterized by the Center for Disease Control and Prevention
(Atlanta, GA) was included as external control.28
Results
Susceptibility tests for macrolides and lincosamides
using the diffusion method
Out of the 200 isolates studied, 12 (6%) of the isolates
were resistant to ERI and 10 (5%) of them to CLI. Fifty
percent of the resistant strains corresponded to serotype III,
25% to serotype V, and the remaining 25% to serotype Ia, II,
and nontypeable (NT) strains. Twelve strains with the fol-
lowing phenotypes were detected with the D-test method:
the cMLSB phenotype in eight strains (66.67%) and the
iMLSB phenotype in four (33.33%) (Table 2).
Fifty percent of the strains presenting the cMLSB phe-
notype corresponded to serotype III. All other serotypes
detected for this phenotype were presented individually: Ia,
II, and V and one NT strain. The eight isolates detected as
cMLSB phenotype also indicated concomitant resistance to
CLI. Out of the strains with the iMLSB phenotype, 60%
corresponded to serotype V, 20% to serotype Ia, and the
remaining 20% to serotype III (Table 2).
Serotype Ia, the one most frequently isolated in this study,
had susceptibility close to 100% for ERI and CLI. Only one
out of the 12 resistant strains belonging to this serotype was
found, showing cMLSB phenotype. On the other hand, no
resistance to macrolides was detected in serotype Ib and IX
strains. No isolation presented phenotype M (Table 2).
Determination of minimum inhibitory concentration
Our results were correlated in the presence of MLSB
phenotype, both constitutively and inducible by both
methods, diffusion (by D-test) and dilution by determination
of the minimum inhibitory concentration (MIC).
The constitutive resistance phenotypes (cMLSB) found
were confirmed by MIC, with moderate resistance values for
resistant strains. Our MIC values were between 1.5 and
Table 2. Strains of Colonizing Streptococcus agalactiae with Resistance to Erythromycin
and Clindamycin: Serotypes, Macrolide Susceptibility Test Results with D-Test and Minimum Inhibitory




MIC (lg/mL) Resistance genes (PCR)
ERI CLI ERI CLI ermB ermTR
141/P III 7 7 N/D cMLSB 2 1 + -
962/P NT 7 6 N/D cMLSB 4 8 + -
1075/P III 6 19 Positive iMLSB 2 2 + -
1090/P V 11 22 Positive iMLSB 2 £0.25 + +
1337/P V 7 8 N/D cMLSB 2 2 + +
1375/P Ia 6 6 N/D cMLSB 1.5 32 + +
8/10 III 7 8 N/D cMLSB 2 2 + -
128/10 III 6 6 N/D cMLSB 2 2 + -
137/10 III 12 12 Negative cMLSB 4 1 + -
369/10 V 6 20 Positive iMLSB 16 0.094 + +
505/10 II 15 11 Negative cMLSB 2 2 + -
36VR III 12 23 Positive iMLSB 4 4 + +
ID, identification number of the Bacteriology Laboratory of the National University of Misiones; D-test, double-disc diffusion test for the
detection of macrolide resistance phenotypes; ERI, erythromycin; CLI, clindamycin; MLSB, macrolide–lincosamide–streptogramin B;
iMLSB, inducible phenotype; cMLSB, constitutive phenotype; MIC, minimum inhibitory concentration; N/D, not detected; +, presence;
-, absence; NT, nontypeable.























































16 mg/mL for ERI, and between 1 and 32 mg/mL for CLI.
Only two of the inducible phenotypes (iMLSB) detected in
our study were confirmed by E-test (Table 2).
Molecular detection of gene resistance to macrolides
and lincosamides
PCR amplification technique. The PCR technique setup
for each primer used was achieved with the following con-
centrations of MgCl2: 1.5 mM for ermTR and 3 mM for ermB.
Resistance genes
Genes ermB and ermTR. Using the primers listed in
Table 1, fragments of size 615 and 360 bp were obtained for
the ermB and ermTR genes, respectively (Fig. 1).
The ermB gene was detected in all constitutive pheno-
types, while the ermTR gene was found in two of them.
In the inducible phenotypes, both genes studied were de-
tected.
Analyzing each gene investigated individually, we ob-
served that
 The ermB gene was detected in the 12 strains that
initially had some macrolide resistance phenotype.
 The ermTR gene was detected in three out of the four
strains with the iMLSB phenotype.
Out of the 25 strains susceptible to ERI and CLI by dif-
fusion and MIC susceptibility tests, the presence of the ermB
gene was detected in 8 of them and the ermTR gene in one
strain (Table 3).
FIG. 1. Macrolide resistance genes. Two percent agarose gel electrophoresis of the polymerase chain reaction products for
the genes: (A) ermB and (B) ermTR. First lane, molecular weight marker, DNA marker (D0017) 100–1,000 bp (Inbio
Highway, Argentina); lanes 2–13 strains Streptococcus agalactiae (group B Streptococcus) 141, 962, 1075, 1090, 1337,
1375, 8/10, 128/10, 137/10, 369/10, 505/10, and 36VR; lane 14 positive control (Streptococcus pneumoniae AZ1 for ermB
gene and Streptococcus agalactiae 6394 for ermTR gene); last lane, negative control.
Table 3. Streptococcus agalactiae Colonizing Strains: Serotypes, Macrolide Susceptibility Test Results
with D-Test and Minimum Inhibitory Concentration, and the Presence of ermB and ermTR Genes




MIC (lg/mL) Resistance genes (PCR)
ERI CLI ERI CLI ermB ermTR
23/04 Ia 25 24 Negative N/D 0.12 0.064 + -
53/04 Ib 24 22 Negative N/D 0.15 0.047 - -
6/P II 30 29 Negative N/D 0.06 0.034 - -
10/P III 24 23 Negative N/D 0.003 0.032 + -
97/P III 24 24 Negative N/D 0.12 0.064 - -
122/P NT 29 27 Negative N/D 0.06 0.064 - -
213/P Ia 22 22 Negative N/D 0.06 0.064 - -
330/P III 26 26 Negative N/D 0.06 0.094 + -
338/P NT 28 27 Negative N/D 0.12 0.064 - -
835/P Ia 28 31 Negative N/D 0.06 0.064 - -
883/P Ia 30 27 Negative N/D 0.06 0.064 + -
901/P II 39 40 Negative N/D 0.12 0.094 - -
934/P II 32 30 Negative N/D 0.12 0.064 - -
1080/P NT 29 32 Negative N/D 0.06 0.032 + -
1155/P Ia 26 28 Negative N/D 0.003 0.032 + -
1265/P Ia 22 22 Negative N/D 0.12 0.064 - -
1297/P Ib 24 26 Negative N/D 0.06 0.064 - -
459/P II 28 27 Negative N/D 0.06 0.094 - -
1485/P II 25 28 Negative N/D 0.12 0.064 - +
A6/P Ia 23 22 Negative N/D 0.06 0.064 + -
A10/P II 24 24 Negative N/D 0.06 0.064 - -
91/10 Ia 22 23 Negative N/D 0.12 0.094 - -
182/10 Ib 24 26 Negative N/D 0.12 0.064 - -
312/10 Ia 26 25 Negative N/D 0.15 0.064 + -
486/10 II 26 25 Negative N/D 0.12 0.062 - -
+, presence; -, absence.























































Bioinformatics analysis of the nucleotide
sequences obtained
The PCR products obtained for each gene were sequenced
and analyzed bioinformatically using the BLASTn algorithm.
The search result showed 99% identity with ermB
(GenBank No. CP007572.1) and ermTR (GenBank No.
CP007631.2) genes.
RAPD technique
A discrimination index equal to one (D = 1) for the OPS11
primer was obtained. The ability to differentiate epidemio-
logically GBS strains was also evaluated with primers
OPB17 and OPB18, but it was not possible to discriminate
conclusive patterns, for both primers, D = 0.84 was obtained.
After the selection of the primer, the RAPD was performed
with the 12 isolates that showed phenotypes of resistance to
ERI and CLI. A maximum distance value of 20% to con-
sider the isolates as a single clone was established a priori.
The 12 isolates were divided into 12 amplification profiles
whose distances range from 47% to 100%. Only two clusters
(137/10, 141/P and 128/10, 08/10) were defined with <55%
distance. Strains 1090/P and 1375/P were not pooled and
presented distance values greater than 95%. The external
group presented no coincidence with the studied strains,
their distance being 100%. There was no correlation be-
tween the clusters and the serotypes expressed by neither
each strain nor any relationship to the resistance phenotype.
Due to the high degree of distance between the isolates, the
12 isolates studied belonged to 12 different clones (Fig. 2).
Discussion
In this study, we found low rates of isolates resistant to
macrolides. We found no elevated macrolide resistance as-
sociated with serotype V. Serotype III presented the highest
resistance. Our results are similar to Lopardo et al.30 for
Argentina, which indicate 5.2% invasive isolates. Souza
et al.31 reported 4.7% resistance to ERI in Brazil, a country
that also borders Argentina, especially our province, while
other researchers showed values of 4.1% and 3% of resis-
tance for ERI and CLI, respectively.14
However, higher rates of resistance have been found in
other geographical areas in South and North America.
Abarzúa et al.32 reported 17.3% of ERI resistance and
13.1% of CLI resistance in GBS strains in Chile, while Back
et al. reported resistance of 50.7% for ERI and 38.4% for
CLI in United States.33 On the other hand, a study carried
out in Spain reported 20.7% of ERI resistance and 17.6% of
CLI resistance.34
In Asia, high values of macrolide resistance were re-
ported: 50% for Taiwan according to Wang et al.35 and 50%
for Korea according to Lee et al.36
Given the high variability of data already available from
both colonizing and invasive strains in different geographic
areas, the probability of inadequate prophylaxis with these
antimicrobials or the need for alternative treatments in these
patients has been raised. These differences in the levels of
susceptibility to ERI and CLI may be due to the policies
applied in the use of antimicrobials in the different regions.
About the relationship between resistant profile and the se-
rotypes detected, our results were similar to those published
FIG. 2. Dendrogram showing the clonal relationships between 12 strains of macrolide-resistant Streptococcus agalactiae
isolated in Misiones province. 1 EXT (External control: Reference strain S. agalactie ss 625).























































by researchers that indicate serotype III as prevalent in its
association with macrolide resistance.37 However, they dif-
fered from the results obtained by Wang et al.35 that show for
Taiwan, other serotypes such as IV and Ib, which surpass
serotype III in its relationship to resistance to macrolides. This
not only shows geographical variability but also the impor-
tance of implementing different antimicrobial policies.
Fröhlicher et al.38 mentioned serotype V associated with
macrolide resistance in the first place. Different studies have
reported that serotype V emerged recently as a cause of
human disease; they have also reported that there is a high
likelihood of acquiring macrolide resistance and dissemi-
nation.39,40 In our study, serotype V appears after serotype
III in relationship to resistance to the above antibiotics.
Serotype V, initially identified as NT, was isolated in the
United States in 1976. At the time of the disposal of the
corresponding sera, it was identified as serotype V. In1980,
it was recognized as a common serotype, not only in the
United States but also in France, Indonesia, Japan, and
Sweden, among other countries. Its isolation from invasive
disease was also frequent in nonpregnant adults, in pregnant
women, and infants with early infection.41
Given the ethnic homogeneity of our patients, we cannot
associate our findings with the ethnicity of pregnant women,
in contrast with Chohan et al.,42 who found an important
association between CLI and ERI resistance in Caucasian
women, which was higher than in African, American, or
Hispanic women. Other authors such as Manning43 reported
associations between high resistance to CLI and black women.
In this study, we found the macrolide resistance mecha-
nism cMLSB associated with the ermB gene with greater
accuracy. The examination of the macrolide resistance
phenotypes detected by diffusion methods is similar to that
published by Lopardo et al.30 for Argentina and Wu et al.44
These authors also found the cMLSB phenotype more fre-
quently. Given the prevalence of the erm gene, susceptibility
to CLI should be reported based on the D-test results.
At present, the emergence of strains resistant to ERI and
CLI32 is well known. The values of resistance to macrolides
and lincosamides in some countries have increased in the
last decade, with some geographic variations and the pos-
sibility of inadequate prophylaxis in these patients, so that it
is necessary to maintain epidemiological surveillance.
The rates of resistance to macrolides have increased un-
interruptedly since the 1990s, so authors such as Campelo
et al.45 insist on close monitoring of their evolution. These
findings lead us to suggest that laboratories should consider
using the D-test to contribute to appropriate treatment of
patients who require it.
It is important to remember that the detection of pheno-
types is beneficial to the installation of the intrapartum an-
tibiotic prophylaxis, since the existence of the phenotype
iMLSB reveals the risk of resistance to CLI.
Our results suggest that those pregnant women with in-
tolerance to penicillin should receive adequate antibiotic
prophylaxis according to the resistance patterns in the re-
gion. Therefore, knowledge of the phenotypes and their
patterns of resistance to ERI and CLI prevalent in a region is
essential for adequate surveillance and appropriate proce-
dures in the control and prevention of infection. This
knowledge also facilitated the selection of strains in the
search for resistance genes in this work. The CLSI recom-
mends confirmation by MIC of macrolide resistance phe-
notypes detected by diffusion.
Our results are similar to Pinheiro et al.46 in the confir-
mation by MIC of these phenotypes. However, they differ in
that, these investigators found high levels of ERI and CLI
resistance with MIC results between 128 and 256 and
‡32mg/mL, respectively, in the nine isolates with the
cMLSB resistance phenotype and three isolates with an
iMLSB resistance phenotype with MIC for ERI in the range
of 16–256 mg/mL.
Our findings can be compared with authors such as
Schoening et al.,47 who described only 14.3% isolates with
iMLSB resistance phenotype, showing CLI resistance by
MIC determination. That is, the inducible resistance to CLI
detected by diffusion is not always accompanied by the
detection of resistance by MIC, which highlights, even
more, the importance of detection of this mechanism of
resistance by phenotypic methods.
The detection of genes associated with macrolide resis-
tance in susceptible strains by D-test, followed by confirma-
tion by MIC, allows us to infer its probable expression in the
presence of environmental stimuli not yet known in GBS.
This bacterium has a recognized capacity to acquire resis-
tance genes from the cervicovaginal and rectal environments.
In this study, we found a close correlation between phe-
notype and genotype, except for the inducible resistance
cases that did not present the ermTR gene. In addition, our
data are comparable with the results obtained by other au-
thors where the isolates presenting the cMLSB phenotype
were mainly associated with the ermB gene, while those
with iMLSB or M phenotype harbored the ermTR gene.
48
These results are similar to Campelo et al.,45 who found a
total correlation between phenotype and genotype.
Our findings differ from Wang et al.,49 who detected
macrolide resistance rates higher than those presented in this
study. However, we agree with the fact that the cMLSB
phenotype is predominant and with the detection of the
ermB gene in all resistant strains. The cMLSB prevalence
pattern is homogeneous in several European and American
series, although the frequency of resistance varies between
8% and 38%.45
Our studies demonstrate that the cMLSB phenotype is as-
sociated with either the ermB or the ermTR gene. This finding
suggests that, in some strains of GBS, the ermTR gene has
mutated in such a way that it is constitutively expressed.50
There were reports of treatment failure in infections due to the
appearance of constitutively resistant mutants.47 It is re-
commended that microorganisms with the iMLSB phenotype
should not be treated with macrolides or lincosamides.
In this study, resistance to iMLSB was associated with the
ermTR gene. In general, some authors51 have reported that
isolates with the iMLSB phenotype had moderately high
MICs to ERI and MIC to CLI in the susceptible category.
Strains with the iMLSB resistance mechanism may show
susceptibility to CLI in vitro by diffusion tests or determi-
nation of MIC, but resistance can be detected by PCR for the
ermTR gene or a positive D-test.
It is important to note that there may be resistant strains
detected by phenotypic methods and the absence of genes
associated with resistance, a situation that can be related to
the variety of genetic mechanisms that can be linked with a
resistance phenotype. In this research, the presence of the























































most reported genes was determined, although there are
other less frequent resistance-determining genes such as
ermC, ermF, ermQ, ermT, msrA, or msrD, all described for
streptococci.52 In addition, mutations in 23S rRNA or genes
encoding ribosomal proteins may also result in possible
causes of ERI resistance in such strains.
The genes associated with macrolide resistance, such as
ermB, ermTR, and mefA, as well as other resistance genes to
other antimicrobial agents, are found on mobile elements
such as plasmids and/or transposons. These genes, mediated
by horizontal transfer, can pass among organisms being
widely disseminated, with consequences not only for a re-
gion but also beyond its borders. This gene transfer further
supports the need for the permanent monitoring of resistance
to phenotypically and genotypically characterized strains,
which will also help our understanding of the acquisition of
new resistance mechanisms.35
We agree with other authors53 that susceptible strains that
carry some of the resistance genes detected may begin to
express them under certain unknown environmental stimuli.
This is an important factor in GBS because it has a recog-
nized ability to acquire resistance genes from the cervi-
covaginal and rectal environment. The increase and spread
of resistance to macrolides and lincosamides, both in GBS
and in other species of streptococci, have already had im-
plications in therapeutics and prophylaxis.
The high transmissibility of hemolytic streptococci, in-
cluding those of macrolide-resistant clones, and the high fre-
quency of use of antibiotics may be responsible for the marked
increase in resistance reported in the last decade.36 The World
Health Organization recommends the monitoring of antimi-
crobial susceptibility, including macrolides and lincosamides,
as well as epidemiological studies, including surveillance of
the dissemination of clonal strains carrying resistance.
Previous studies on GBS suggest that the RAPD is an
epidemiological technique superior to serotyping for the
evaluation of this pathogen. This technique has the advan-
tage of being able to differentiate the strains within a spe-
cific serotype. Our results coincide with Martı́nez et al.28
and show that a correlation in serotype and different RAPD
patterns cannot be established.
These results indicate that classification based on serologi-
cal traits, traditionally used for epidemiological investigations,
may not reflect the clonal relationships between GBS isolates.
This observation supports the idea that the RAPD might be
more successful than serotyping in the differentiating of the
GBS strains because it is fast, easy to perform, and useful in
routine epidemiological investigations.54 Moreover, these ep-
idemiological studies will be greatly benefited by the dis-
criminatory power of molecular techniques, which is higher
with respect to phenotypic typing methods.
Zhang et al.54 support the RAPD technique for epidemi-
ological purposes because the isolates are tested in duplicate
or triplicate, and only the amplicons occurring in both cases
are taken into consideration. In addition, the technique was
performed with an interval of 12 months and the results
obtained were similar in all cases.
In this research, the discrimination index obtained using
OPS11 primer was equal to one, which emphasizes its utility
and ability to discriminate between nongenetically related
isolates. Our results show that genetic diversity exists not
only between different serotypes but also within a given se-
rotype. The resistance to macrolides in the province of Mis-
iones is due to a multiclonal spread since the distance
obtained between the different isolates was in all cases >47%.
In addition, the groupings, although distant, showed no
relationship with the serotype or with the resistance pheno-
type observed. Similar percentages of phenotypes cMLSB
and iMLSB were observed by Brzychczy-Włoch et al.,
55 who
concluded that the dissemination resistance was due to both
clonal dissemination and horizontal transmission between
strains. This does not coincide with the results obtained by
Campelo et al.,45 where it was observed that 67.9% of the
MLSB strains are grouped into four clones. This information
is of the utmost importance when monitoring the emergence
of new resistant strains since it can lead to the selection of
more reasonable and effective therapies.
A detailed genetic analysis of the different strains isolated
from GBS in other regions of the country and of the world
could contribute to a better understanding of the biological
diversity and epidemiological aspects involved in the
transmission of diseases caused by GBS.
To date, no information has been found in similar studies
at the regional level, which encourages the continuation of
our research to contribute to the knowledge of resistance in
GBS and to collaborate with the prevention and improve-
ment of the treatment of these infections.
The importance of the phenotypic and genotypic char-
acterization of macrolide resistance in GBS strains is crucial
to contribute to the intrapartum prophylactic antibiotic
therapy of allergic pregnant women, to the epidemiological
surveillance of these strains, and to the knowledge of the
distribution and frequency of their appearance as a prereq-
uisite for the design of vaccine strategies.56
We emphasize the importance of the implementation of a
control program of maternal colonization by GBS between
35 and 37 weeks of gestation, combining serotyping and
RAPD patterns for the study of this microorganism, as well
as the use of an intrapartum treatment regimen in 100% of
cases in which infection has been detected.
It is important to highlight the need to continue similar
studies that allow the epidemiological surveillance of cir-
culating serotypes and the carrying and expression of re-
sistance genes in GBS strains to contribute to the study of
GBS disease and prevent its outcome in newborns. Epide-
miological surveillance of the susceptibility of GBS to
penicillin and other antimicrobials of choice such as mac-
rolides in b-lactam allergic patients is necessary to ensure
adequate treatments and to detect new resistance mecha-
nisms or strains with decreased susceptibility.
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R. Pallarés, and R. Martı́n. 2005. Distribution of subclasses
mefA and mefE of the mefA gene among clinical isolates of
macrolide-resistant (M-phenotype) Streptococcus pneumo-
niae, Viridans group streptococci, and Streptococcus pyo-
genes. Spanish Pneumococcal Infection Study Network.
Antimicrob. Agents Chemother. 49:827–829.
54. Zhang, G., M. Kotiw, and G. Daggard. 2002. A RAPD-PCR
genotyping assay which correlates with serotypes of group
B streptococci. Lett. Appl. Microbiol. 35:247–250.
55. Brzychczy-Włoch, M.,T. Gosiewski, D. Pawlik,
A. Szumała-Kakol, A. Samead, and P. Heczko. 2012. Oc-
currence of the hypervirulent ST-17 clone of Streptococcus
agalactiae in pregnant women and newborns. Przegl. Epi-
demiol. 66:395–401.
56. Chen, V., F. Avci, and D. Kasper. 2013. A maternal vac-




Associate Professor of Bacteriology
Microbiology Department
Institute of Biotechnology Misiones
‘‘Dra. Marı́a Ebe Reca’’ (InBioMis)
Faculty of Exact, Chemical
and Natural Sciences (FCEQyN)
National University of Misiones (UNaM)
Research Associate of the CONICET (National Council
for Scientific and Technical Research)




10 NOVOSAK ET AL.
D
ow
nl
oa
de
d 
by
 L
in
ko
pi
ng
s 
U
ni
ve
ri
st
et
sb
ib
lio
te
k 
fr
om
 w
w
w
.li
eb
er
tp
ub
.c
om
 a
t 0
4/
22
/2
0.
 F
or
 p
er
so
na
l u
se
 o
nl
y.
 
